METHOD FOR DETERMINING CARDIOTOXIC COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA Russian patent published in 2012 - IPC A61B5/145 A61K31/704 A61P35/00 G01N27/26 G01N33/573 G01N33/561 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology and haematology, and may be used for determining cardiotoxic complications in patients suffering chronic lymphatic leukemia and treated with polychemotherapy. Patient's blood serum is examined, and if observing no signs of infectious-inflammatory process and haemolysis, then blood is examined for lactate dehydrogenase by standartised UV test at temperature 37°C; the lactate dehydrogenase isoenzyme ratio is shown by enzyme electrophoresis, while enzyme linked immunosorbent assay provides calculating a tumour necrosis factor-α level. The examinations and assays run in with introducing chemopreparations and repeated in a week following the introduction and further throughout the whole polychemotherapeuty course in the same regiment, and in the end of the therapeutic course - once a month during the whole follow-up period. The lactate dehydrogenase level increasing by more than 510 IU/l and tumour necrosis factor-α increasing by more than 35 pg/ml, the lactate dehydrogenase-1 to lactate dehydrogenase-2 ratio increasing by more than 1 give evidence of potential development of cardiotoxicity of the chemopreparations in the patients, and subsequently, of life-threatening rhythm disturbances.

EFFECT: method enables well-timed, early determination of developing cardiotoxic complications of the chemotherapy in the given group of patients.

1 ex